SG11202110301TA - Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof - Google Patents
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereofInfo
- Publication number
- SG11202110301TA SG11202110301TA SG11202110301TA SG11202110301TA SG11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- bioconjugates
- coli
- production
- antigen polysaccharides
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 title 1
- 239000005017 polysaccharide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819746P | 2019-03-18 | 2019-03-18 | |
| PCT/US2020/023404 WO2020191082A1 (en) | 2019-03-18 | 2020-03-18 | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110301TA true SG11202110301TA (en) | 2021-10-28 |
Family
ID=70285927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110301TA SG11202110301TA (en) | 2019-03-18 | 2020-03-18 | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11446370B2 (ko) |
| EP (1) | EP3941516A1 (ko) |
| JP (1) | JP7370391B2 (ko) |
| KR (1) | KR102532707B1 (ko) |
| CN (1) | CN113924112A (ko) |
| AR (1) | AR118388A1 (ko) |
| AU (1) | AU2020240072A1 (ko) |
| BR (1) | BR112021018236A2 (ko) |
| CA (1) | CA3134216A1 (ko) |
| CL (1) | CL2021002426A1 (ko) |
| CO (1) | CO2021013823A2 (ko) |
| CR (1) | CR20210522A (ko) |
| EA (1) | EA202192390A1 (ko) |
| IL (1) | IL286394A (ko) |
| JO (1) | JOP20210256A1 (ko) |
| MA (1) | MA55364A (ko) |
| MX (1) | MX2021011445A (ko) |
| PE (1) | PE20212265A1 (ko) |
| SG (1) | SG11202110301TA (ko) |
| TW (1) | TWI751513B (ko) |
| UY (1) | UY38616A (ko) |
| WO (1) | WO2020191082A1 (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014111516A1 (en) | 2013-01-17 | 2014-07-24 | Arsanis Biosciences Gmbh | Mdr e. coli specific antibody |
| FI3110441T3 (fi) | 2014-02-24 | 2024-05-06 | Glaxosmithkline Biologicals Sa | Uusi polysakkaridi ja sen käyttöjä |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| JP2022525773A (ja) | 2019-03-18 | 2022-05-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大腸菌ｏ抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法 |
| MX2021011445A (es) | 2019-03-18 | 2021-10-13 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos. |
| CN115803087A (zh) * | 2020-09-17 | 2023-03-14 | 杨森制药公司 | 多价疫苗组合物及其用途 |
| IL301880A (en) | 2020-11-30 | 2023-06-01 | Janssen Pharmaceuticals Inc | Analytical method for glycoconjugation using a capillary-based immunoassay system |
| MX2023011697A (es) | 2021-04-01 | 2023-10-19 | Janssen Pharmaceuticals Inc | Produccion de bioconjugados o18 de e. coli. |
| CN117098550A (zh) | 2021-04-08 | 2023-11-21 | 杨森制药公司 | 生物缀合物生产方法 |
| CN116003531B (zh) * | 2022-12-28 | 2023-09-05 | 山东省农业科学院畜牧兽医研究所 | 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） | アジュバント含有ワクチン組成物 |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| EP0971739B1 (en) | 1997-04-01 | 2004-10-06 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| AU750587B2 (en) | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
| CA2396762A1 (en) | 2000-04-13 | 2001-10-25 | Corixa Corporation | Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| WO2001078787A2 (en) | 2000-04-18 | 2001-10-25 | Endobiologics, Incorporated | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| EP1481057B1 (en) | 2002-03-07 | 2006-02-15 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| US9845344B2 (en) | 2004-03-30 | 2017-12-19 | Hoba Therapeutics Aps | Therapeutic use of a growth factor, NsG33 |
| EP1888761B1 (en) | 2005-05-11 | 2010-09-29 | ETH Zurich | Recombinant n-glycosylated proteins from procaryotic cells |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2964398C (en) | 2007-09-14 | 2023-03-07 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US20100286067A1 (en) | 2008-01-08 | 2010-11-11 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
| EP3427749A1 (en) | 2008-02-20 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| CA2760096C (en) | 2009-04-27 | 2018-10-30 | Immuron Limited | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder. |
| PT2437753T (pt) | 2009-06-05 | 2016-11-23 | Infectious Disease Res Inst | Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos |
| TR201803015T4 (tr) | 2009-11-19 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Prokaryotik hücrelerde immünojenik polisakaridler üreten biyosentetik sistem. |
| DK3336225T3 (da) | 2010-07-16 | 2020-03-30 | Adimab Llc | Antistofbiblioteker |
| RU2013131795A (ru) | 2010-12-10 | 2015-01-20 | Мерк Шарп Энд Домэ Корп. | Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций |
| JP2014526449A (ja) | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| US20150238596A1 (en) | 2012-09-10 | 2015-08-27 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| TR201904022T4 (tr) | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
| JP2016501550A (ja) | 2012-12-27 | 2016-01-21 | グリコヴァキシン アーゲー | Ｃｒｍ１９７に関する方法及び組成物 |
| WO2014111516A1 (en) | 2013-01-17 | 2014-07-24 | Arsanis Biosciences Gmbh | Mdr e. coli specific antibody |
| MY175308A (en) | 2013-05-18 | 2020-06-18 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| SG11201602546RA (en) | 2013-10-11 | 2016-04-28 | Glycovaxyn Ag | Methods of host cell modification |
| JP2016540764A (ja) | 2013-12-04 | 2016-12-28 | グリコヴァキシン アーゲー | 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防 |
| JP6590413B2 (ja) | 2014-02-06 | 2019-10-16 | エックスフォー・ファーマシューティカルズ（オーストリア）ゲーエムべーハー | 大腸菌特異的抗体配列 |
| FI3110441T3 (fi) | 2014-02-24 | 2024-05-06 | Glaxosmithkline Biologicals Sa | Uusi polysakkaridi ja sen käyttöjä |
| SI3131577T1 (sl) | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| PT3240895T (pt) | 2014-12-30 | 2022-03-02 | Glaxosmithkline Biologicals Sa | Composições e métodos para glicosilação de proteínas |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| MX2021011445A (es) | 2019-03-18 | 2021-10-13 | Janssen Pharmaceuticals Inc | Bioconjugados de polisacaridos de antigenos o de e. coli, metodos de produccion y metodos de uso de los mismos. |
| JP2022525773A (ja) | 2019-03-18 | 2022-05-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 大腸菌ｏ抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法 |
| FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
| CN115803087A (zh) | 2020-09-17 | 2023-03-14 | 杨森制药公司 | 多价疫苗组合物及其用途 |
-
2020
- 2020-03-18 MX MX2021011445A patent/MX2021011445A/es unknown
- 2020-03-18 JO JOP/2021/0256A patent/JOP20210256A1/ar unknown
- 2020-03-18 MA MA055364A patent/MA55364A/fr unknown
- 2020-03-18 TW TW109109075A patent/TWI751513B/zh active
- 2020-03-18 EP EP20718989.5A patent/EP3941516A1/en active Pending
- 2020-03-18 BR BR112021018236A patent/BR112021018236A2/pt unknown
- 2020-03-18 JP JP2021556247A patent/JP7370391B2/ja active Active
- 2020-03-18 CN CN202080037067.6A patent/CN113924112A/zh active Pending
- 2020-03-18 UY UY0001038616A patent/UY38616A/es unknown
- 2020-03-18 EA EA202192390A patent/EA202192390A1/ru unknown
- 2020-03-18 AU AU2020240072A patent/AU2020240072A1/en active Pending
- 2020-03-18 SG SG11202110301TA patent/SG11202110301TA/en unknown
- 2020-03-18 PE PE2021001476A patent/PE20212265A1/es unknown
- 2020-03-18 CR CR20210522A patent/CR20210522A/es unknown
- 2020-03-18 US US16/822,340 patent/US11446370B2/en active Active
- 2020-03-18 KR KR1020217033424A patent/KR102532707B1/ko active IP Right Grant
- 2020-03-18 AR ARP200100746A patent/AR118388A1/es unknown
- 2020-03-18 WO PCT/US2020/023404 patent/WO2020191082A1/en active Application Filing
- 2020-03-18 CA CA3134216A patent/CA3134216A1/en active Pending
-
2021
- 2021-09-14 IL IL286394A patent/IL286394A/en unknown
- 2021-09-16 CL CL2021002426A patent/CL2021002426A1/es unknown
- 2021-10-14 CO CONC2021/0013823A patent/CO2021013823A2/es unknown
-
2022
- 2022-07-28 US US17/815,705 patent/US11931405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113924112A (zh) | 2022-01-11 |
| CA3134216A1 (en) | 2020-09-24 |
| US20200316184A1 (en) | 2020-10-08 |
| CR20210522A (es) | 2021-12-17 |
| MX2021011445A (es) | 2021-10-13 |
| WO2020191082A9 (en) | 2020-11-05 |
| CO2021013823A2 (es) | 2022-03-29 |
| IL286394A (en) | 2021-10-31 |
| US20230118878A1 (en) | 2023-04-20 |
| PE20212265A1 (es) | 2021-11-30 |
| TWI751513B (zh) | 2022-01-01 |
| AR118388A1 (es) | 2021-09-29 |
| MA55364A (fr) | 2022-01-26 |
| CL2021002426A1 (es) | 2022-04-29 |
| US11446370B2 (en) | 2022-09-20 |
| BR112021018236A2 (pt) | 2021-11-23 |
| JP7370391B2 (ja) | 2023-10-27 |
| EP3941516A1 (en) | 2022-01-26 |
| JOP20210256A1 (ar) | 2023-01-30 |
| US11931405B2 (en) | 2024-03-19 |
| AU2020240072A1 (en) | 2021-10-28 |
| JP2022533883A (ja) | 2022-07-27 |
| KR20210141586A (ko) | 2021-11-23 |
| EA202192390A1 (ru) | 2021-12-03 |
| WO2020191082A1 (en) | 2020-09-24 |
| KR102532707B1 (ko) | 2023-05-12 |
| UY38616A (es) | 2020-09-30 |
| TW202102255A (zh) | 2021-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286394A (en) | Biological conjugates of polysaccharides e. coli o - antigen, methods for their production and methods for using them | |
| IL286467A (en) | Methods for producing biological conjugates of polysaccharides e. coli o - antigen, their preparations and methods of using them | |
| EP3668497A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER, INFLAMMATION, OR IMMUNE-REACTION-ASSOCIATED DISEASES | |
| MX2019012534A (es) | Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico. | |
| IL272919A (en) | Metabolic engineering of e. coli for the biosynthesis of cannabinoid products | |
| EP3733809A4 (en) | WATER-REPELLENT COMPOSITION AND METHOD FOR MANUFACTURING A WATER-REPELLENT FIBER PRODUCT | |
| EP3684434A4 (en) | TISSUE CONSTRUCTION, METHODS FOR PRODUCING AND USING THE SAME | |
| EP4293033A3 (en) | Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides | |
| WO2015164392A8 (en) | Novel anti-rnf43 antibodies and methods of use | |
| ZA202008011B (en) | Polyether derivatives, uses, and methods of making the same | |
| MX2020002885A (es) | Derivados de galnac. | |
| MX2019008546A (es) | Usos terapeuticos de un polvo de insectos. | |
| IL262747A (en) | Anti-kv1.3 antibodies, methods for their production and use | |
| EP3518985A4 (en) | AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES | |
| EP3720842A4 (en) | ACYLHYDRAZONE LINKERS, METHODS, AND USES THEREOF | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| WO2017096303A3 (en) | Cerdulatinib for treating hematological cancers | |
| MX2018005785A (es) | Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos. | |
| MX2019013250A (es) | 2,3,7-trimetiloct-6-enil acetato y 3,7-dimetil-2-metilen-oct-6-eni l acetato y derivados de estos y su uso como sustancias quimicas aromaticas. | |
| EP3622830A4 (en) | GROOVED NOODLES, PROCESS FOR PRODUCING GROOVED NOODLES AND PROCESS FOR COOKING GROOVED NOODLES | |
| EP3612549A4 (en) | LANTIBIOTICS, LANTIBIOTIC-PRODUCING BACTERIA, COMPOSITIONS AND METHOD OF MANUFACTURING AND USING THEREOF | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| SG11202104018TA (en) | An implantable construct, methods of manufacturing, and uses thereof | |
| EP3700569A4 (en) | H1.0K180ME2 ANTIBODIES, METHOD OF MANUFACTURING AND USES THEREOF | |
| WO2018148629A3 (en) | Methods and compositions for treating neurodegeneration and fibrosis |